Characterization of Glycosylation in the Fc Region of Therapeutic Recombinant Monoclonal AntibodyApplications | 2017 | Agilent TechnologiesInstrumentationHPLC, LC/TOF, LC/HRMS, LC/MSIndustriesPharma & BiopharmaManufacturerAgilent TechnologiesKey wordsglycan, mab, glycoform, papain, glycosylation, mass, glyco, rapid, region, assignment, glycans, fab, turnaround, accurate, recombinant, charge, chip, profile, tof, counts, agilent, digestion, therapeutic, analysis, monoclonal, intact, from, assignments, mau, shortened, afforded, reversed, validation, separations, characterization, poroshell, gylcan, microcentrifugation, diffusion, core, deconvoluted, enriches, porous, zhu, antibody, creative, narrow, estimations, peaks, fucosylated
Similar PDF
Agilent BioHPLC Columns - Characterization of NIST Monoclonal Antibody Critical Quality Attributes - Application Compendium
2019|Agilent Technologies|Guides
Agilent BioHPLC ColumnsCharacterization of NIST MonoclonalAntibody Critical Quality AttributesApplication Compendium ContentsAgilent-NISTmAb Standard (P/N 5191-5744; 5191-5745) was aliquoted fromNISTmAb RM 8671 batch. Quality control (QC) testing is performed usingAgilent LC-MS system. QC batch release test includes aggregate profile, chargevariants and intact mass...
Key words
mab, mabglycan, glycanadvancebio, advancebiomapping, mappingpeptide, peptidecounts, countsmonoclonal, monoclonalagilent, agilentglycans, glycansmin, minprotein, proteinnistmab, nistmabmass, masscolumn, columnantibody
N-Glycan analysis of monoclonal antibodies and other glycoproteins using UHPLC with fluorescence detection
2016|Agilent Technologies|Applications
N-Glycan analysis of monoclonalantibodies and other glycoproteinsusing UHPLC with fluorescencedetectionAgilent 1260 Infinity Bio-inert QuaternaryLC System with Agilent 1260 InfinityFluorescence DetectorApplication NoteBiopharmaceuticalsLUAuthorsG02000 0A 0G8 1317.49Sonja Schneider, Edgar Nägele6Agilent Technologies, Inc.4Waldbronn, Germany2G0F2100 0A 0G1463.55 (1,6) G1F(1,3) G1F2110 0A 0GG2FMan5 1625.602120 0A 0GMan51787.65741235.44G2FS12121...
Key words
glycan, glycanglycans, glycansglycosylation, glycosylationfluorescence, fluorescenceglycoproteins, glycoproteinsmonoclonal, monoclonalantibody, antibodylinked, linkedpngase, pngaseconalbumin, conalbuminpattern, patternovalbumin, ovalbuminmabs, mabsglycoprofil, glycoprofilqtof
BioPharma Applications Compendium - AGILENT APPLICATIONS FOR BIOPHARMACEUTICAL DISCOVERY, DEVELOPMENT AND QA/QC
2015|Agilent Technologies|Guides
BioPharma Applications CompendiumAGILENT APPLICATIONS FORBIOPHARMACEUTICAL DISCOVERY,DEVELOPMENT AND QA/QCssssPLAYRPLAYRQSMAYRQSM N NFSM N NFGHN NFGH MAXIMIZE DEVELOPMENTAND ENSURE QUALITYAs you move from biopharmaceutical discovery intodevelopment, your success depends on encountering asfew surprises as possible.Enjoy the confidence of knowing the exact state of yourbiomolecule...
Key words
monoclonal, monoclonalagilent, agilentantibody, antibodyprotein, proteinantibodies, antibodiesanalysis, analysisusing, usingglycan, glycanelectrophoresis, electrophoresispeptide, peptidemapping, mappingsolutions, solutionsbio, biozorbax, zorbaxcharacterization
High Resolution Glycopeptide Mapping of EPO Using an Agilent AdvanceBio Peptide Mapping Column
2017|Agilent Technologies|Applications
High Resolution GlycopeptideMapping of EPO Using an AgilentAdvanceBio Peptide MappingColumnApplication NoteBioPharmaAuthorsAbstractJames Martosella, Phu Duong, andThe 2.7 µm Agilent AdvanceBio Peptide Mapping column is specifically designed toAlex Zhuimprove separations of peptide and peptide mapping applications. The column isAgilent Technologies, Inc.based on...
Key words
rhepo, rhepovysnflr, vysnflrmapping, mappingeaenittgcaehcslnenitvpdtkvnfyawk, eaenittgcaehcslnenitvpdtkvnfyawkvnfyawkr, vnfyawkrpeptide, peptidelfrvysnflr, lfrvysnflrvysnflrgk, vysnflrgkvlerylleakeaenittgcaehcslnenitvpdtk, vlerylleakeaenittgcaehcslnenitvpdtkvnfyawk, vnfyawkadvancebio, advancebioeaenittgcaehcslnenitvpdtkvnfyawkr, eaenittgcaehcslnenitvpdtkvnfyawkrvysnflrgklk, vysnflrgklkylleakeaenittgcaehcslnenitvpdtkvnfyawk, ylleakeaenittgcaehcslnenitvpdtkvnfyawkdigest